Combining Esketamine and Prolonged Exposure Treatment for PTSD (Post Traumatic Stress Disorder)

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

June 9, 2025

Primary Completion Date

December 30, 2025

Study Completion Date

December 30, 2025

Conditions
Post Traumatic Stress Disorder PTSD
Interventions
DRUG

Esketamine (Intranasal Spray)

Esketamine doses will be administered via insufflation with a starting dose of 1 spray of 14 mg per nostril (28 mg/total). Based on tolerability, total dose will be increased to a target dose of 84 mg delivered as three bouts separated by 5 minutes per bout (total dose administered in 15 minutes).

BEHAVIORAL

Massed Prolonged Exposure (PE)

Eligible participants will be enrolled to receive 10 sessions of PE delivered in massed (daily) format over 2 weeks (weekdays, not including weekends and holidays)

Trial Locations (1)

78229

RECRUITING

The University of Texas Health Science Center at San Antonio, San Antonio

All Listed Sponsors
collaborator

Institute for Integration of Medicine & Science-UT Health San Antonio

UNKNOWN

lead

The University of Texas Health Science Center at San Antonio

OTHER